Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations

@inproceedings{Yoshino2014RandomizedPI,
  title={Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations},
  author={Takayuki Yoshino and Yoshito Komatsu and Yasuhide Yamada and Kentaro Yamazaki and Akihito Tsuji and Takashi Ura and Axel M Grothey and Eric Van Cutsem and Andrea Veiga Wagner and Frank Cihon and Yoko Hamada and Atsushi Ohtsu},
  booktitle={Investigational New Drugs},
  year={2014}
}
Background In the international, phase III, randomized, double-blind CORRECT trial, regorafenib significantly prolonged overall survival (OS) versus placebo in patients with metastatic colorectal cancer (mCRC) that had progressed on all standard therapies. This post hoc analysis evaluated the efficacy and safety of regorafenib in Japanese and non-Japanese subpopulations in the CORRECT trial. Methods Patients were randomized 2 : 1 to regorafenib 160 mg once daily or placebo for weeks 1–3 of each… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

subgroup analysis of Japanese patients from RECORD-1

  • T Tsukamoto, N Shinohara, carcinoma Tsuchiya N et al Phase III trial of everolimus in cell
  • Jpn J Clin Oncol 41:17–24 Invest New Drugs
  • 2015
1 Excerpt

Similar Papers

Loading similar papers…